UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
UV1 is a therapeutic cancer vaccine that has been explored in prostate and lung cancers, and
in combination with ipilimumab in malignant melanoma. This study will explore the safety,
tolerability and efficacy of UV1 administered with GM-CSF in melanoma patients who are also
receiving pembrolizumab.